Illumina Inc
NASDAQ:ILMN
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
98.2977
155.15
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Illumina Inc
Illumina Inc
Other Liabilities
Illumina Inc
Other Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Illumina Inc
NASDAQ:ILMN
|
Other Liabilities
$926m
|
CAGR 3-Years
-21%
|
CAGR 5-Years
1%
|
CAGR 10-Years
19%
|
|
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
Other Liabilities
$4.3B
|
CAGR 3-Years
3%
|
CAGR 5-Years
7%
|
CAGR 10-Years
15%
|
|
|
Danaher Corp
NYSE:DHR
|
Other Liabilities
$5.6B
|
CAGR 3-Years
-12%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
3%
|
|
|
Mettler-Toledo International Inc
NYSE:MTD
|
Other Liabilities
$289.8m
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
5%
|
|
|
Agilent Technologies Inc
NYSE:A
|
Other Liabilities
$708m
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-11%
|
|
|
IQVIA Holdings Inc
NYSE:IQV
|
Other Liabilities
$800m
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
17%
|
|
Illumina Inc
Glance View
In the world of genomics, Illumina Inc. stands as a pioneer, reshaping the landscape of genetic sequencing with a precision that borders on artistry. This San Diego-based company, founded in 1998, has become an industry cornerstone by unlocking the potential of the human genome through its advanced sequencing technologies. Illumina's success is anchored in its innovative creation of next-generation sequencing platforms, which enable researchers to analyze DNA at a scale and speed previously thought impossible. By providing the tools that sequence, analyze, and interpret vast amounts of genetic data, Illumina plays a crucial role in driving discoveries in personalized medicine, agriculture, and countless other fields. At the heart of Illumina's business model lies its suite of sequencing instruments and consumables, which form the backbone of its revenue generation. Their sequencing machines, ranging from behemoth instruments capable of cracking the human genome to compact devices used for focused applications, operate much like a razor-and-blade model. Once customers invest in Illumina's platforms, they continue to purchase consumable products, including reagents and advanced software, crucial for each sequencing run. This model not only fosters continuous engagement with their user base but also sustains a steady revenue stream. By expanding its reach into genomic-based clinical applications, Illumina has also started tapping into diagnostic markets, promising to transform the future of healthcare while ensuring sustained growth for the company.
See Also
What is Illumina Inc's Other Liabilities?
Other Liabilities
926m
USD
Based on the financial report for Sep 29, 2024, Illumina Inc's Other Liabilities amounts to 926m USD.
What is Illumina Inc's Other Liabilities growth rate?
Other Liabilities CAGR 10Y
19%
Over the last year, the Other Liabilities growth was -26%. The average annual Other Liabilities growth rates for Illumina Inc have been -21% over the past three years , 1% over the past five years , and 19% over the past ten years .
You don't have any saved screeners yet
